ClinicalTrials.gg
Sign In

Drug

PARP1 Inhibitor HRS-1167 clinical trials

Also written HRS-1167.

studies test it
3
open now
2
in phase 3
0
first study started
2022

Keep track of what changes. Save the PARP1 Inhibitor HRS-1167 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Development codes

HRS-1167
2

Studies by the year they started

3 studies that test it; most in 2022 (1)

Studies that test PARP1 Inhibitor HRS-1167, by start year
YearStudies
20221
20241
20251

By phase

A phase 1/2 study counts in both.

Phase 1
3
Phase 2
1

What it is tested for

Each study’s main condition, where its own words name it.

Prostatic Neoplasms
1
Neoplasms
1

Who runs them

Industry 3 · Other 0

Jiangsu HengRui Medicine Co., Ltd. (2) · EMD Serono Research & Development Institute, Inc. (1)

Often tested with

Tested in the same studies.

Prednisone acetate (1) · Prednisone (1)

Studies

Open first, then newest update. How each study uses PARP1 Inhibitor HRS-1167 is read from its arms, and is right about nine times in ten.

Testing it · 3

Given in every arm · 4 — PARP1 Inhibitor HRS-1167 is usual care beside what is tested